NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmonic Inc. ("Harmonic Inc.") (NASDAQ:HLIT) concerning possible violations of federal securities laws. Harmonic reported its third quarter financial results on February 10, 2025.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Walgreens Boots Alliance, Inc. (NASDAQ:WBA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/walgreens-boots-alliance-inc-lawsuit-submission-form-2?prid=130972&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=130981&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Avis Budget Group, Inc. ("Avis Budget") (NASDAQ:CAR) concerning possible violations of federal securities laws. Avis Budget issued a press release on February 11, 2025, reporting its financial results for the fourth quarter and full year 2024.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your ModivCare Inc. (NASDAQ:MODV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/modivcare-inc-lawsuit-submission-form?prid=130965&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130970&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Trade Desk, Inc. ("The Trade Desk") (NASDAQ:TTD) concerning possible violations of federal securities laws. The Trade Desk reported Q4 revenue of $741 million, falling well below the company's prior guidance from its November 7, 2024, earnings call, where The Trade Desk projected "at least" $756 million in revenue.Following these results, shares of The Trade Desk Inc. fell over 30%.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Olin Corporation ("Olin Corporation") (NYSE:OLN) concerning possible violations of federal securities laws. Olin issued a press on January 30, 2025, reporting its financial results for the fourth quarter of 2024.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your FMC Corporation (NYSE:FMC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fmc-corporation-lawsuit-submission-form?prid=130975&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=130951&wire=1 or contact Joseph E.

Cloud communications specialist Bandwidth (BAND -6.57%) reported mixed fourth-quarter financial results on Thursday, Feb. 20. A key highlight was generating record revenue of $210 million, up 27% year over year and exceeding analyst consensus estimates of $203 million.

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

After snapping its 20-day win streak earlier this week, is Meta Platforms (META) stock overdue for a split? Citi senior analyst of Internet Equity Research Ron Josey says that a split is unlikely, going on to underline Meta's user growth across its platforms — Facebook, Instagram, Threads — and growth in AI spending and advertising revenue.

Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.

ETSY's Q4 2024 earnings beat estimates. However, revenues miss due to lower gross merchandise sales.

When investors think about monster stocks that went stratospheric over the past decade, companies like Nvidia (NASDAQ:NVDA) quickly come to mind.

Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.

Cheniere Energy (LNG -0.50%), a global player in liquefied natural gas (LNG) production and export, announced its Q4 2024 financial results on Feb. 20, 2025. Earnings exceeded analysts' expectations for earnings per share (EPS) but showed a decline in revenue and net income from the previous year.